B-cell subsets, signaling and their roles in secretion of autoantibodies

Lupus

Volumn 25, Issue 8, 2016, Pages 850-856

  Iwata, S ^a   Tanaka, Y ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

B cell; Btk; JAK; SLE; Syk

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; CD27 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 21; INTERLEUKIN 4; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PROTEIN KINASE B; PROTEIN KINASE SYK; RITUXIMAB; STAT1 PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; AGAMMAGLOBULINAEMIA TYROSINE KINASE; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE; SYK PROTEIN, HUMAN;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; DISEASE ACTIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IN VITRO STUDY; LIPID RAFT; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION;

AUTOANTIBODIES; B-LYMPHOCYTE SUBSETS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SYK KINASE; TOLL-LIKE RECEPTORS;

EID: 84973327659     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316643172     Document Type: Article

References (78)

1. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533.
2. Sanz I, Wei C, Lee FE, Anolik J,. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008; 20: 67-82.
3. Manjarrez-Orduño N, Quách TD, Sanz I,. B cells and immunological tolerance. J Investig Dermatol 2009; 129: 278-288.
4. Chan OT, Shlomchik MJ,. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 1998; 160: 51-59.
5. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ,. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189: 1639-1648.
6. Chan OT, Madaio MP, Shlomchik MJ,. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999; 169: 107-121.
7. Dörner T, Jacobi AM, Lipsky PE,. B cells in autoimmunity. Arthritis Res Ther 2009; 11: 247-247.
8. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165: 5970-5979.
9. Dörner T, Foster SJ, Farner NL, Lipsky PE,. Immunoglobulin kappa chain receptor editing in systemic lupus erythematosus. J Clin Invest 1998; 102: 688-694.
10. Dörner T, Farner NL, Foster SJ, Lipsky PE,. Immunoglobulin light chain usage in early SLE: Indications for receptor editing of both V kappa and V lambda light chains. Arthritis Rheum 1999; 42: S52-S52.
11. Nimmerjahn F, Ravetch JV,. Fc-receptors as regulators of immunity. Adv Immunol 2007; 96: 179-204.
12. Ettinger R, Kuchen S, Lipsky PE,. Interleukin 21 as a target of intervention in autoimmune disease. Ann Rheum Dis 2008; 67: 83-86.
13. Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008; 58: 1762-1773.
14. Wei C, Anolik J, Cappione A, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007; 178: 6624-6633.
15. Klein U, Rajewsky K, Küppers R,. Human immunoglobulin (Ig)M(+)IgD(+) peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998; 188: 1679-1689.
16. Fecteau JF, Côté G, Néron S,. A new memory CD27(-)IgG(+) B cell population in peripheral blood expressing V-H genes with low frequency of somatic mutation. J Immunol 2006; 177: 3728-3736.
17. Ma CS, Pittaluga S, Avery DT, et al. Selective generation of functional somatically mutated IgM(+)CD27(+), but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease. J Clin Invest 2006; 116: 322-333.
18. Rodríguez-Bayona B, Ramos-Amaya A, Pérez-Venegas JJ, Rodríguez C, Brieva JA,. Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients. Arthritis Res Ther 2010; 12: R108-R108.
19. Weller S, Faili A, Garcia C, et al. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci U S A 2001; 98: 1166-1170.
20. Kruetzmann S, Rosado MM, Weber H, et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 2003; 197: 939-945.
21. Shi Y, Agematsu K, Ochs HD, Sugane K,. Functional analysis of human memory B-cell subpopulations: IgD+CD27+ B cells are crucial in secondary immune response by producing high affinity IgM. Clin Immunol 2003; 108: 128-137.
22. Weller S, Braun MC, Tan BK, et al. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a pre-diversified immunoglobulin repertoire. Blood 2004; 104: 3647-3654.
23. Carsetti R, Rosado MM, Donnanno S, et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol 2005; 115: 412-417.
24. Alexander T, Thiel A, Rosen O, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009; 113: 214-223.
25. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-3590.
26. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233.
27. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-1226.
28. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
29. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA,. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677.
30. Rastetter W, Molina A, White CA,. Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004; 55: 477-503.
31. Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007; 17: 191-197.
32. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66: 470-475.
33. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients. Arthritis Rheum 2009; 61: 482-487.
34. Iwata S, Saito K, Tokunaga M, Tanaka Y,. B-cell or T-cell-dominant recurrence after rituximab therapy in patients with SLE. Ann Rheum Dis 2012; 71: 1749-1750.
35. Iwata S, Saito K, Tokunaga M, et al. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in long-term remission after B cell depletion therapy with rituximab. J Rheumatol 2011; 38: 633-641.
36. Iwata S, Saito K, Tokunaga M, Tanaka Y,. Persistent memory B cell down-regulation after 6-year remission induced by rituximab therapy in patients with systemic lupus erythematosus. Lupus 2013; 22: 538-540.
37. Tabrizi SJ, Niiro H, Masui M, et al. T cell leukemia/lymphoma 1 and galectin-1 regulate survival/cell death pathways in human naive and IgM+ memory B cells through altering balances in Bcl-2 family proteins. J Immunol 2009; 182: 1490-1499.
38. Enders A, Bouillet P, Puthalakath H, Xu Y, Tarlinton DM, Strasser A,. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J Exp Med 2003; 198: 1119-1126.
39. Grimaldi CM, Hicks R, Diamond B,. B cell selection and susceptibility to autoimmunity. J Immunol 2005; 174: 1775-1781.
40. Keren Z, Melamed D,. Antigen receptor signaling competence and the determination of B cell fate in B-lymphopoiesis. Histol Histopathol 2005; 20: 187-196.
41. Grammer AC, Fischer R, Lee O, Zhang X, Lipsky PE,. Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals. Arthritis Res Ther 2004; 6: 28-38.
42. Liossis S, Kovacs B, Dennis G, Kammer GM, Tsokos GC,. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996; 98: 2549-2557.
43. Mackay M, Stanevsky A, Wang T, et al. Selective dysregulation of the FcγIIB receptor on memory B cells in SLE. J Exp Med 2006; 203: 2157-2164.
44. Wu XN, Ye YX, Niu JW, et al. Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus. Sci Transl Med 2014; 6: 246ra99-246ra99.
45. Taher TE, Parikh K, Flores-Borja F, et al. Protein phosphorylation and kinome profiling reveal altered regulation of multiple signaling pathways in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2010; 62: 2412-2423.
46. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA,. Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2007; 56: 291-302.
47. Huck S, Le Corre R, Youinou P, Zouali M,. Expression of B cell receptor-associated signaling molecules in human lupus. Autoimmunity 2001; 33: 213-224.
48. Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008; 358: 900-909.
49. Kozyrev SV, Abelson AK, Wojcik J, et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet 2008; 40: 211-216.
50. Pradhan V, Borse V, Ghosh K,. PTPN22 gene polymorphisms in autoimmune diseases with special reference to systemic lupus erythematosus disease susceptibility. J Postgrad Med 2010; 56: 239-242.
51. Hunter T,. The age of crosstalk: Phosphorylation, ubiquitination, and beyond. Mol Cell 2007; 28: 730-738.
52. Ruprecht CR, Lanzavecchia A,. Toll-like receptor stimulation as a third signal required for activation of human naïve B cells. Eur J Immunol 2006; 36: 810-806.
53. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK,. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 2063-2073.
54. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV,. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006; 203: 553-561.
55. Krieg AM,. A role for Toll in autoimmunity. Nat Immunol 2002; 3: 423-424.
56. Taniguchi T, Kobayashi T, Kondo J, et al. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem 1991; 266: 15790-15796.
57. Wong WS, Leong KP,. Tyrosine kinase inhibitors: A new approach for asthma. Biochim Biophys Acta 2004; 1697: 53-69.
58. Beaven MA, Baumgartner RA,. Downstream signals initiated in mast cells by Fc epsilon RI and other receptors. Curr Opin Immunol 1996; 8: 766-772.
59. Kulathu Y, Grothe G, Reth M,. Autoinhibition and adapter function of Syk. Immunol Rev 2009; 232: 286-299.
60. Bahjat FR, Pine PR, Reitsma A, et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008; 58: 1433-1444.
61. Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC,. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 2010; 62: 2086-2092.
62. Iwata S, Yamaoka K, Niiro H, et al. Amplification of Toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation. J Allergy Clin Immunol 2012; 129: 1594-1601.
63. Iwata S, Yamaoka K, Niiro H, et al. Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus. Lupus 2015; 24: 695-704.
64. Fleischer SJ, Giesecke C, Mei HE, Lipsky PE, Daridon C, Dörner T,. Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus. Arthritis Rheum 2014; 66: 3424-3435.
65. Satterthwaite AB, Li Z, Witte ON,. Btk function in B cell development and response. Semin Immunol 1998; 10: 309-316.
66. Kil LP, de Bruijn MJ, van Nimwegen M, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 2012; 119: 3744-3756.
67. Conley ME, Cooper MD,. Genetic basis of abnormal B cell development. Curr Opin Immunol 1998; 10: 399-406.
68. Khan WN,. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase. Immunol Res 2001; 23: 147-156.
69. Thien CB, Langdon WY,. Cbl: Many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001; 2: 294-307.
70. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88-92.
71. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010; 107: 13075-13080.
72. Wang SP, Iwata S, Nakayamada S, et al. Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation. Rheumatology (Oxford) 2015; 54: 1488-1497.
73. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A,. The JAK-STAT pathway: Impact on human disease and therapeutic intervention. Annu Rev Med 2015; 66: 311-328.
74. O'Shea JJ, Pesu M, Borie DC, Changelian PS,. A new modality for immunosuppression: Targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004; 3: 555-564.
75. Nosaka T, van Deursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science 1995; 270: 800-802.
76. Russell SM, Johnston JA, Noguchi M, et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: Implications for XSCID and XCID. Science 1994; 266: 1042-1045.
77. Wang SP, Iwata S, Nakayamada S, Sakata K, Yamaoka K, Tanaka Y,. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis 2014; 73: 2213-2215.
78. Onda M, Ghoreschi K, Steward-Tharp S, et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol 2014; 193: 48-55.